Biotechs investigate mitochondria-targeting drugs to claim a share in the weight loss drug market dominated by GLP-1RAs.

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

The FDA greenlit multiple new drugs this month and issued some notable label expansions including for Eli Lilly’s Kisunla.

A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...

Eli Lilly (LLY) stock in focus as its diabetes drug Mounjaro causes heart benefits suceeding in a late-stage trial versus its ...

Eli Lilly’s blockbuster diabetes drug Mounjaro matched the ability of an older treatment to prevent major heart complications ...

Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...

Neurizon Therapeutics, Arovella Therapeutics and Singular Health Group are among ASX health companies reporting quarterly ...

Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...

Cognito Therapeutics has presented new data demonstrating its Spectris neuromodulation device’s potential to slow cognitive decline and preserve white matter in patients with mild to moderate ...

The moves come after the S&P 500 and the Nasdaq Composite hit new all-time and closing highs during Monday’s trading session.

The therapies, which are just starting to enter clinical trials, will need to prove clear clinical and quality-of-life ...